Assays and substrates

Transglutaminases are defined as R-glutaminyl-peptide: amine γ-glutamyltransferase (EC They use a modified double-displacement mechanism to carry out an acyl transfer reaction between the γ-carboxamide group of a peptide-bound glutamine residue and the ε-amino group of a peptide-bound lysine. The active site consists of a catalytic triad (Cys, His and Asp).
The active site cysteine reacts with the γ-carbox-amide of the glutamine, forming a γ-glutamyl thioester releasing ammonia. This activated species subsequently reacts with nucleophilic primary amines, yielding either an isopeptide bond (pathway 1) or a (γ-glutamyl)amine bond (pathway 2). When an amine is not available, the acyl-enzyme intermediate reacts with water to yield glutamic acid (pathway 3).

Reaction pathway of transglutaminase
Transglutaminase reaction pathway

The incorporation of dansylcadaverine into casein (compare to pathway 2) leads to an increase in fluorescence intensity. The principle is used in kit T036.

During the transpeptidation reaction ammonia (NH3) is released. The amount of ammonia can be monitored using glutamate dehydrogenase and NADPH as co-factor. Dependent on the transglutaminase either casein or synthetic peptides serve as acyl donor substrates. The reaction can be monitored online using a UV photometer at 340 nm. An activity assays using this principle is available for MTG (M001).

The kit M003 is most sensitive allowing detection of TG2 in the picogram range using the incorporation of biotinylated peptides to microtiter plates displaying primary amines on the surface.

TG2 - Enzyme Immuno Assay (EIA):
The kit E018 is dedicated to determine the overall quantity of TG2. The principle behind is a sandwich EIA based on two monoclonal antibodies against tissue transglutaminase (TG2). The kit provides coated plates and all reagents necessary including a tissue transglutaminase calibrator.

The chromogenic assay kit Z009 uses Z-Gln-Gly as the amine acceptor substrate and hydroxylamine as amine donor. In the presence of transglutaminase, hydoxylamine is incorporated forming glutamyl-hxdroxamate which develops a colored complex with iron (III) detectable at 525 nm (red).

The reverse reaction of TGs is measured in the isopeptidase assays F001 (FXIII).


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageSuccessful ISO9001:2015 recertification
  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis


  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering


  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy